Resources

For the latest in nextgen biomed, sign up for our monthly newsletter to be among the first to receive exclusive insights, in-depth market analyses, and expert articles directly to your inbox

Gene Therapy Development

Abundant Stochastic Off-Target Activity by Base Editors

Can complementary approaches for off-target quantification demonstrate substantial levels in various state-of-the-art editors?
NextGen Therapeutics

Bispecific Antibodies for Solid Tumours

Laura von Schantz, Vice President of Discovery at Alligator Bioscience, leads a discussion on the current and future opportunities of bispecific antibodies for solid tumour treatment.

European Approval for Monkeypox Vaccine

The European Commission (EC) has approved Bavarian Nordic’s Imvanex vaccine which protects against monkeypox, and diseases caused by the vaccinia virus.
Gene Therapy Development

When to Cut and When to Inhibit? A Low-Throughput, Hands-On Investigation Of CRISPR-Cut and CRISPRi Efficiencies In iPSC And Neural Cells

Gene knockdown – the manual reduction of a particular gene's expression in target cells – entails the modification of cellular development in young cells. CRISPR gene editing techniques enable researchers such as Pia Johansson to induce gene knockdown in target cells.
Gene Therapy Development

Overcoming the Challenges of Precision Genome Editing

Experts from academia and industry discuss the current obstacles and opportunities for genome editing during a roundtable session at Gene Therapy Development & Manufacturing: In-Person.

Discussion Group Announcement

Oxford Global’s next round of Biologics Discussion Groups announced.
3D Cell Culture

Speaker Insights – In Conversation with Pedro-Caetano Pinto

Discover key insights into the application of microphysiological systems for advanced kidney and prostate cancer research.
Antibody & Protein Engineering

Widening the Therapeutic Window: Development of Antibody Drug Conjugates for Solid Tumours

Compared to non-solid tumours, solid tumours are more difficult to treat with conventional therapeutic methods. Antibody drug conjugates – biopharmaceutical drugs designed as a targeted therapy for treating cancer – represent a viable treatment alternative.
Antibody & Protein Engineering

Novartis Withdraws Tislelizumab Submission

Novartis scraps US submission of tislelizumab as a monotherapy for non-small cell lung cancer.
Drug Discovery & Development

Addressing Immunotherapy Resistance Through PVRIG And TIGIT Blockade

In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.

New Speakers Announced: Vaccines Europe Congress 2022

Exciting updates revealed about upcoming Vaccines Europe: In-Person congress happening 29-30 November 2022.
Drug Discovery & Development

Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors

Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things discovery